Anika Therapeutics (NSDQ:ANIK) said last week that it agreed to pay former chief medical officer Dr. Stephen Mascioli $350,000 “for all alleged damages and attorneys’ fees.” In return, Mascioli agreed not to pursue legal action against the Bedford, Mass.-based company. Mascioli departed from Anika in January this year, after spending less than a year there. According […]
OpGen prices $10m public offering
OpGen (NSDQ:OPGN) said earlier this month that it priced a $10 million public offering of 25 million units of common stock and warrants at 40¢ apiece. The molecular diagnostics company said each common warrant has an exercise price of 43¢ per share and expires five years after issuance. The offering is slated to close tomorrow. […]
Mobile diagnostic device detects tumor cells in blood
Researchers from the Rovira i Virgili University have developed and patented a mobile diagnostic device that can detect tumor cells in blood, according to a study published in Scientific Reports. The team reported that the device can quantify tumor cells in a blood sample in real-time, positioning it as a tool to boost the diagnosis and […]
Whitehouse Labs expands drug delivery device testing capabilities
Whitehouse Laboratories, a division of Albany Molecular Research, said today that it has expanded its drug delivery device testing capabilities to include services for ISO 80369 standards. The 8 standards described in ISO 80369 were designed to prevent connector errors in medical device and drug delivery systems. Whitehouse Labs said that the group’s latest expansion […]
Titan Pharmaceuticals partners for long-acting antimalarial implant
Titan Pharmaceuticals (NSDQ:TTNP) this month revealed a collaboration with the Walter Reed Army Institute of Research to evaluate the use of its ProNeura drug-delivery technology for the long-term prevention of malaria. The company is already working to develop its implant for an array of applications. Titan president & CEO Sunil Bhonsle told Drug Delivery Business News that this […]
EU antitrust officials charge Teva in ‘pay-for-delay’ deal
Antitrust regulators in the European Union charged Teva Pharmaceuticals (NYSE:TEVA) today, accusing the company of arranging an illegal deal with Cephalon to delay the sale of a cheap generic version to Cephalon’s sleep disorder drug, modafinil. The EU competition officials have unleashed a series of fines against an array of companies in recent years over similar […]
CDC chief propped up controversial anti-aging medicine in private practice
Before the newly-appointed CDC head Dr. Brenda Fitzgerald ran the public health department for the state of Georgia, she was a board-certified OB/GYN with a private practice. But according to a report from Forbes, she not only provided women’s healthcare in the 30 years she practiced medicine – she was also a fellow in “anti-aging medicine.” […]
Abbott launches tender offer for Alere in $5.3B merger
Abbott (NYSE:ABT) said today that it launched the tender offer for its $5.3 billion acquisition of diagnostics giant Alere (NYSE:ALR). The $402-per-share tender offer is slated to expire at midnight on August 11, Abbott said. The merger was amended in April, when Abbott agreed to pay $5.3 billion for Alere rather than the original price […]
AntriaBio raises $13m for injectable, once-weekly insulin
AntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co. According to the deal, investors paid $1.00 per share of common stock. The Louisville, Colo.-based company said it plans to use the proceeds for general corporate purposes, including the Phase I study of its […]
Trovagene raises $7m for precision cancer therapies
Trovagene (NSDQ:TROV) said today that it inked a deal with unnamed investors to sell approximately $7.1 million of its common stock. According to the deal, Trovagene plans to sell 6,191,500 shares of common stock. In a concurrent private placement, the biotech said it will issue warrants to buy up to 4,643,626 shares of common stock. […]